Jump to content

Clazakizumab: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
m wikilink
 
(24 intermediate revisions by 16 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{drugbox
{{drugbox
| type = mab
| type = mab
Line 25: Line 26:
| excretion =
| excretion =
| CAS_number = 1236278-28-6
| CAS_number = 1236278-28-6
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4S38Z8RA9O
| ATCvet =
| ATCvet =
| ATC_prefix = none
| ATC_prefix = none
Line 31: Line 34:
| ChemSpiderID = none
| ChemSpiderID = none
| DrugBank =
| DrugBank =
| KEGG = D10312
| C=6426 | H=9972 | N=1724 | O=2032 | S=42
| C=6426 | H=9972 | N=1724 | O=2032 | S=42
| synonyms = ALD518, BMS-945429
| molecular_weight = 145.2 kg/mol
}}
}}


'''Clazakizumab''' (formerly ALD518 and BMS-945429), an [[investigational drug]], is a [[aglycosylated]], humanized [[monoclonal antibody]] against [[interleukin-6]].<ref name="Handbook">{{cite book|editor1-link=Stefan Dübel, Janice M. Reichert (eds)|title=Handbook of Therapeutic Antibodies, Volume 2|date=2007|publisher=Wiley Blackwell|page=987|url=https://books.google.com/books?id=svHsBQAAQBAJ&pg=PA987&lpg=PA987&dq=Clazakizumab,+BMS-945429+ALD518&source=bl&ots=OSkfdXWflh&sig=SDM6MUhRVekTcRVaQ6SgemQgXAw&hl=en&sa=X&ved=0ahUKEwjW6a-ipdnRAhUpxlQKHUHrCMwQ6AEIPTAG#v=onepage&q=Clazakizumab%2C%20BMS-945429%20ALD518&f=false|accessdate=January 23, 2017}}</ref> Clazakizumab was developed by [[Bristol Myers Squib]] and [[Alder Biopharmaceuticals]]. A preliminary randomized, double-blind, placebo-controlled, [[phase 2 clinical trial|phase 2]] dose-ranging study of clazakizumab in psoriasis patients reported that the antibody lacked a [[dose-response effect]].<ref name="ArthRheum1">{{cite journal|author1=Mease PJ, Gottlieb AB, et al.|title=The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis.|journal=Arthritis Rheumatol|date=2016 Sep|volume=68|issue=9|pages=2163-73|doi=doi: 10.1002/art.39700.|accessdate=January 23, 2017}}</ref>
'''Clazakizumab''' (formerly '''ALD518''' and '''BMS-945429'''), an [[investigational drug]], is an [[aglycosylated]], humanized rabbit [[monoclonal antibody]] against [[interleukin-6]].<ref name="Handbook">{{cite book|title=Handbook of Therapeutic Antibodies, Volume 2|date=2007|publisher=Wiley Blackwell|page=987|isbn=9783527329373|url=https://books.google.com/books?id=svHsBQAAQBAJ&q=Clazakizumab,+BMS-945429+ALD518&pg=PA987|access-date=January 23, 2017}}</ref> Clazakizumab was developed by [[Bristol Myers Squib]] and [[Alder Biopharmaceuticals]]. A preliminary randomized, double-blind, [[placebo]]-controlled, [[phase 2 clinical trial|phase 2]] dose-ranging study of clazakizumab in [[psoriatic arthritis]] patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of [[psoriatic arthritis]]; however, the antibody lacked a [[dose-response effect]].<ref name="ArthRheum1">{{cite journal|vauthors=Mease PJ, Gottlieb AB|display-authors=etal|title=The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis.|journal=Arthritis Rheumatol|date=September 2016|volume=68|issue=9|pages=2163–73|doi=10.1002/art.39700|pmid=27059799|s2cid=3644962}}</ref>


==See also==
==See also==
Line 47: Line 51:
{{Interleukin receptor modulators}}
{{Interleukin receptor modulators}}


[[Category:Bristol-Myers Squibb]]
[[Category:Drugs developed by Bristol Myers Squibb]]
[[Category:Antibodies]]
[[Category:Antibodies]]
[[Category:Anti-inflammatory agents]]
[[Category:Experimental monoclonal antibodies]]
[[Category:Experimental drugs]]
[[Category:Experimental cancer drugs]]

Latest revision as of 07:01, 2 December 2023

Clazakizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetIL6
Clinical data
Other namesALD518, BMS-945429
Routes of
administration		infusion
ATC code
  • none
Legal status
Legal status
  • investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6426H9972N1724O2032S42
Molar mass145239.02 g·mol−1

Clazakizumab (formerly ALD518 and BMS-945429), an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6.[1] Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals. A preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect.[2]

See also

[edit]

References

[edit]
  1. ^ Handbook of Therapeutic Antibodies, Volume 2. Wiley Blackwell. 2007. p. 987. ISBN 9783527329373. Retrieved January 23, 2017.
  2. ^ Mease PJ, Gottlieb AB, et al. (September 2016). "The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis". Arthritis Rheumatol. 68 (9): 2163–73. doi:10.1002/art.39700. PMID 27059799. S2CID 3644962.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Clazakizumab&oldid=1187917121"